Diabetes Foot Health Access and Modernization Act of 2026

S.4070 was introduced on March 12, 2026, by Sen. Young (R-IN) with four cosponsors, and referred to the Senate Finance Committee. The bill has two main provisions: (1) amending Medicaid to treat podiatrists (DPMs) as physicians for covered services, and (2) clarifying Medicare documentation requirements for therapeutic shoes for diabetics. The bill is in its earliest stage—referred to committee with no hearings or markups. No funding is appropriated; it is a statutory change to coverage definitions. The Medicaid provision effectively expands the pool of eligible providers for foot and ankle care, potentially increasing utilization. The Medicare provision reduces administrative burden for diabetic shoe coverage. Both changes are narrow in scope. The companion bill, H.R. 7905, was introduced in the House and referred to Energy & Commerce and Ways & Means. Legislative momentum is low: the bill has only two actions (introduction and referral), and no committee action in three months. The sponsors are not committee chairs (Sen. Young is a junior member). The policy area is health, but the impact is limited to podiatry and diabetic foot care—a small segment of healthcare spending. There are no publicly traded pure-play podiatry or diabetic shoe companies. Large diversified healthcare insurers (UNH, CI) would see administrative adjustments but negligible financial impact. Hospital operators (HCA) might see a slight uptick in foot care volumes. Given the early stage and narrow scope, the market impact is negligible.